Brokerages Set AstraZeneca PLC (LON:AZN) Target Price at £104.12

AstraZeneca PLC (LON:AZN) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is £104.12 ($130.53).

A number of analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £110 ($137.90) price objective on shares of AstraZeneca in a report on Tuesday, September 3rd. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a £140 ($175.50) price target on shares of AstraZeneca in a research note on Friday. Finally, Berenberg Bank reiterated a “buy” rating and set a £150 ($188.04) price objective on shares of AstraZeneca in a research note on Monday, September 2nd.

Insider Activity at AstraZeneca

In other news, insider Pascal Soriot bought 20,000 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was purchased at an average cost of £102.03 ($127.91) per share, for a total transaction of £2,040,600 ($2,558,104.55). Also, insider Michel Demare purchased 2,000 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were purchased at an average cost of GBX 118 ($1.48) per share, for a total transaction of £2,360 ($2,958.51). Insiders purchased a total of 23,500 shares of company stock valued at $223,316,000 in the last quarter. Insiders own 0.04% of the company’s stock.

AstraZeneca Trading Up 4.1 %

Shares of AZN stock opened at £104.74 ($131.30) on Friday. AstraZeneca has a 12-month low of GBX 9,461 ($118.60) and a 12-month high of £133.88 ($167.83). The company has a market capitalization of £162.35 billion, a PE ratio of 3,325.08, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The firm has a 50 day moving average price of £113.52 and a two-hundred day moving average price of £120.66. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.